Patents by Inventor Bart Harper
Bart Harper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10351558Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.Type: GrantFiled: February 12, 2016Date of Patent: July 16, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Dongfang Meng, Hong Li, Meng Yang, Manuel de Lera Ruiz, Sunita V. Dewnani, Tianying Jian, Dann L. Parker, Jr., Ting Zhang, Louis-Charles Campeau, Harold B. Wood, Jiayi Xu, Richard Berger, Jane Yang Wu, Robert K. Orr, Shawn P. Walsh, Bart Harper
-
Patent number: 10285989Abstract: The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: May 10, 2016Date of Patent: May 14, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Dong-Ming Shen, Deping Wang, XiaoXia Qian, Bart Harper, Meng Yang, Yingjian Bo
-
Patent number: 10214512Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.Type: GrantFiled: October 24, 2016Date of Patent: February 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
-
Publication number: 20180339977Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein.Type: ApplicationFiled: October 24, 2016Publication date: November 29, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson, Eric Mertz, Santhosh F. Neelamkavil, Weiguo Liu, Wanying Sun, Dong-Ming Shen, Bart Harper, Cheng Zhu, Thomas Bara, Yeon-Hee Lim, Meng Yang
-
Publication number: 20180256575Abstract: The present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: May 10, 2016Publication date: September 13, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Dong-Ming Shen, Deping Wang, XiaoXia Qian, Bart Harper, Meng Yang, Yingjian Bo
-
Patent number: 10065945Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.Type: GrantFiled: January 20, 2015Date of Patent: September 4, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Richard Berger, Timothy A. Blizzard, Brian T. Campbell, Helen Y. Chen, John S. Debenham, Sunita V. Dewnani, Byron Dubois, Candido Gude, Zack Zhiqiang Guo, Bart Harper, Zhiyong Hu, Songnian Lin, Ping Liu, Ming Wang, Feroze Ujjainwalla, Jiayi Xu, Libo Xu, Rui Zhang
-
Publication number: 20180022747Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.Type: ApplicationFiled: February 12, 2016Publication date: January 25, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Dongfang Meng, Hong Li, Meng Yang, Manuel de Lera Ruiz, Sunita V. Dewnani, Tianying Jian, Dann L. Parker, Jr., Ting Zhang, Louis-Charles Campeau, Harold B. Wood, Jiayi Xu, Richard Berger, Jane Yang Wu, Robert K. Orr, Shawn P. Walsh, Bart Harper
-
Publication number: 20180009796Abstract: The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.Type: ApplicationFiled: January 20, 2015Publication date: January 11, 2018Inventors: Richard Berger, Timothy A. Blizzard, Brian T. Campbell, Helen Y. Chen, John S. Debenham, Sunita V. Dewnani, Byron Dubois, Candido Gude, Zack Zhiqiang Guo, Bart Harper, Zhiyong Hu, Songnian Lin, Ping Liu, Ming Wang, Feroze Ujjainwalla, Jiayi Xu, Libo Xu, Rui Zhang
-
Patent number: 9815796Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.Type: GrantFiled: December 17, 2014Date of Patent: November 14, 2017Assignees: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhiqiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
-
Publication number: 20170015633Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 17, 2014Publication date: January 19, 2017Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhi Qiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
-
Patent number: 8501786Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: GrantFiled: March 23, 2009Date of Patent: August 6, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Bart Harper, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Dong-Ming Shen, Liping Wang, Harvey Wendt, Cheng Zhu
-
Patent number: 8354403Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: GrantFiled: August 17, 2010Date of Patent: January 15, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Edmondson, Richard Berger, Lehua Chang, Vincent J. Colandrea, Jeffrey J. Hale, Bart Harper, Nam Fung Kar, Bing Li, Greg J. Morriello, Christopher R. Moyes, Deyou Sha, Dong-Ming Shen, Liping Wang, Harvey Wendt, Cheng Zhu
-
Publication number: 20120157432Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: ApplicationFiled: August 17, 2010Publication date: June 21, 2012Applicant: Merck Sharp & Dohme, Corp.Inventors: Scott D. Edmondson, Richard Berger, Lehua Chang, Vincent j. Colandrea, Jeffrey J. Hale, Bart Harper, Nam Fung Kar, Bing Li, Greg J. Morriello, Christopher R. Moyes, Deyou Sha, Dong-Ming Shen, Liping Wang, Harvey Wendt, Cheng Zhu
-
Patent number: 7884104Abstract: The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Type: GrantFiled: September 27, 2005Date of Patent: February 8, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Jason M. Cox, Scott D. Edmondson, Bart Harper, Ann E. Weber
-
Publication number: 20110028461Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.Type: ApplicationFiled: March 23, 2009Publication date: February 3, 2011Inventors: Richard Berger, Lehua Chang, Scott D. Edmondson, Stephen D. Goble, Bart Harper, Nam Fung Kar, Ihor E. Kopka, Bing Li, Gregori J. Morriello, Chris R. Moyes, Dong-Ming Shen, Liping Wang, Harvey Wendt, Cheng Zhu
-
Publication number: 20080076773Abstract: The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Type: ApplicationFiled: September 27, 2005Publication date: March 27, 2008Inventors: Jason Cox, Scott Edmondson, Bart Harper, Ann Weber